On September 17, 2026 AbbVie (NYSE: ABBV) reported that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results demonstrated statistically significant and clinically meaningful improvements in objective response rate (ORR) and progression-free survival (PFS), with etentamig meeting the dual primary endpoints versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Beyond the full CERVINO data, AbbVie will present research demonstrating the breadth of its myeloma pipeline across T-cell engagers, targeted therapies, rational combinations and real-world evidence. Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings.
Additional presentations from these investigational assets will explore treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes, reinforcing AbbVie’s strategy to advance understanding of disease heterogeneity, mechanisms of resistance and the evolving needs of patients living with multiple myeloma.
"Despite meaningful progress in multiple myeloma, the disease remains incurable and patients continue to face challenges related to treatment resistance, disease heterogeneity, tolerability and durable disease control," said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology at AbbVie. "Our presence at IMS reflects the depth and momentum of our multiple myeloma strategy as we advance our scientifically differentiated portfolio, spanning T-cell engagers, targeted therapies and rational combinations designed to address distinct disease mechanisms and evolving patient needs, with the goal of delivering more precise, durable and accessible treatment options."
The full list of AbbVie presentations at IMS includes:
Note: All presentation times are listed in local Glasgow time.
Abstract Title
Date/Time
Session
Abstract Number
Real-World (RW)
Characteristics, Treatment
Patterns, and Outcomes
in Triple-Class Exposed
(TCE)
Relapsed/Refractory
Multiple Myeloma
(RRMM) in Europe:
Results from the
HARMONY Big
Data Platform
Wednesday,
September 23, 2026
12:00–1:00 PM
Poster Presentation
PA-386
Etentamig in Patients with
Relapsed/Refractory
Multiple Myeloma (RRMM)
with Prior Exposure to B-
Cell Maturation Antigen
(BCMA)-Targeted
Therapy
Thursday, September
24, 2026
12:00–1:00 PM
Poster Presentation
PA-181
A Phase 1/2, Open-Label,
Platform Study to
Evaluate the Safety and
Efficacy of Etentamig
Monotherapy or
Combination Therapy in
Patients with Multiple
Myeloma
Friday, September 25,
2026
12:00–1:00 PM
Poster Presentation
PA-008
Phase 1/2, Open-Label,
Platform Study of
Surzetoclax with
Etentamig in Biomarker-
Selected Patients with
Relapsed/Refractory
Multiple Myeloma (RRMM)
Friday, September 25,
2026
12:00–1:00 PM
Poster Presentation
PA-346
Real-World (RW)
Infection-Related
Healthcare Resource
Utilization (HCRU) and
Costs in Patients (pts)
with Multiple Myeloma
(MM) Receiving
T-cell Redirecting
Therapies (TCRTs)
Friday, September 25,
2026
12:00–1:00 PM
Poster Presentation
PA-387
CERVINO: Phase (Ph) 3
Results of Etentamig vs
Investigator’s Choice of
Standard Available
Therapies (SAT) in
Patients (Pts) With Triple-
Class
Exposed Relapsed or
Refractory Multiple
Myeloma
(RRMM)
Friday, September 25,
2026
3:00–5:00 PM
Plenary Session
Hall 5
LBA-01
Etentamig Combined With
Pomalidomide Plus
Dexamethasone
(Pom+Dex) in Relapsed/
Refractory Multiple
Myeloma (RRMM) After
1–3
Prior Lines of Therapy: A
Phase 1b Dose-
Escalation and Safety
Expansion Study
Saturday, September
26, 2026
8:30–9:30 AM
Oral Presentation
Abstract Session 9
Hall 5
OA-24
AbbVie Advances ABBV-
2001/ISB 2001: A Unique,
Single-Molecule
Trispecific T-cell Engager
(TCE) Approach Toward
Robust Anti-Myeloma
Activity with Superior
Tumor Cytotoxicity
Saturday, September
26, 2026
9:30–10:20 AM
Oral Presentation
Future Targets and
New Modalities of
Therapy
Hall 5
N/A
Surzetoclax: A Potentially
Best-in-Class BCL-2
Inhibitor for the Treatment
of Multiple Myeloma
with t(11;14) Translocation
or High BCL-2
Expression
N/A
Poster Presentation
PA-468
More information about the IMS 2026 meeting, including AbbVie’s presence, will be available here.
Additional information around AbbVie’s ongoing clinical trials in multiple myeloma can be found at clinicaltrials.gov.
Etentamig, ABBV-2001 (ISB 2001) and surzetoclax are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.
(Press release, AbbVie, SEP 17, 2026, View Source [SID1234670927])